BerganKDV Wealth Management’s Charles River Laboratories CRL Stock Holding History

BerganKDV Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6	Closed	-$1.21K	–	911
2023 Q1	$1.21K	Hold	6	–	–	﹤0.01%	885
2022 Q4	$1.31K	Hold	6	–	–	﹤0.01%	849
2022 Q3	$1K	Sell	6 -9	-60%	-$1.94K	﹤0.01%	869
2022 Q2	$3K	Hold	15	–	–	﹤0.01%	758
2022 Q1	$4K	Hold	15	–	–	﹤0.01%	747
2021 Q4	$6K	Hold	15	–	–	﹤0.01%	746
2021 Q3	$6K	Hold	15	–	–	﹤0.01%	721
2021 Q2	$6K	Hold	15	–	–	﹤0.01%	675
2021 Q1	$4K	Hold	15	–	–	﹤0.01%	686
2020 Q4	$4K	Buy	15 +5	+50%	+$1.19K	﹤0.01%	683
2020 Q3	$2K	Hold	10	–	–	﹤0.01%	688
2020 Q2	$2K	Sell	10 -12	-55%	-$1.92K	﹤0.01%	737
2020 Q1	$3K	Buy	22 +4	+22%	+$600	﹤0.01%	655
2019 Q4	$3K	Buy	+18	New	+$2.49K	﹤0.01%	702

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

BerganKDV Wealth Management's CRL Position: Q2 2023 in Review

BerganKDV Wealth Management sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 6 shares — an estimated $1.21K sold.

BerganKDV Wealth Management first reported a position in CRL in Q4 2019 and held it in 14 quarters. The position peaked at $6K in Q4 2021. 611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

BerganKDV Wealth Management reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
BerganKDV Wealth Management sold 6 Charles River Laboratories shares in Q2 2023, an estimated $1.21K.
BerganKDV Wealth Management first reported a position in Charles River Laboratories in Q4 2019 and held it in 14 quarters.
BerganKDV Wealth Management's Charles River Laboratories position peaked at $6K in Q4 2021.
611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on BerganKDV Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.